National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press, 2017.
Hasin, DS, Sarvet, AL, Cerdá, M, Keyes, KM, Stohl, M, Galea, S, et al.
US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. JAMA Psychiatry
2017; 74: 579–88.
Hall, W, Lynskey, M.
Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction
2016; 111: 1764–73.
Murray, RM, Englund, A, Abi-Dargham, A, Lewis, DA, Di Forti, M, Davies, C, et al.
Cannabis-associated psychosis: neural substrate and clinical impact. Neuropharmacology
2017; 124: 89–104.
Marconi, A, Di Forti, M, Lewis, CM, Murray, RM, Vassos, E.
Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull
2016; 42: 1262–9.
Colizzi, M, Iyegbe, C, Powell, J, Blasi, G, Bertolino, A, Murray, RM, et al.
Interaction between DRD2 and AKT1 genetic variations on risk of psychosis in cannabis users: a case-control study. NPJ Schizophr
2015; 1: 15025.
Englund, A, Freeman, TP, Murray, RM, McGuire, P.
Can we make cannabis safer?
2017; 4: 643–8.
Altintas, M, Inanc, L, Oruc, GA, Arpacioglu, S, Gulec, H.
Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients. Neuropsychiatr Dis Treat
2016; 12: 1893–900.
Schoeler, T, Petros, N, Di Forti, M, Klamerus, E, Foglia, E, Ajnakina, O, et al.
Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. Lancet Psychiatry
2016; 3: 947–53.
Colizzi, M, Carra, E, Fraietta, S, Lally, J, Quattrone, D, Bonaccorso, S, et al.
Substance use, medication adherence and outcome one year following a first episode of psychosis. Schizophr Res
2016; 170: 311–7.